INVESTOR RELATIONS

CEO comment

November 12

With a solid evidence platform and supported by strong partnerships, we put the final pieces of the puzzle into place during the third quarter for the design of the clinical study that will evaluate our drug candidate arfolitixorin as a new potential component in the treatment of colorectal cancer. Few drug candidates in the clinical development phase that we are in have as broad a scientific base as arfolitixorin – and all new data, from preclinical studies to analyses of the previous phase III study AGENT, indicate that the new study design offers greater possibilities for arfolitixorin to demonstrate its full potential, says CEO, Petter Segelman Lindqvist.

Read the press release >>

Petter Segelman Lindqvist
Petter Segelman Lindqvist, CEO

INVESTORS – latest reports and presentations

SEE HOW ARFOLITIXORIN
WORKS IN CANCER CELLS

About arfolitixorin

Want to know more about the the drug candidate arfolitxorin?

Last updated 11-12-2024

Scroll to Top